Cargando…

A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?

To investigate the potential treatment evolution and outcome improvement, we retrospectively compared clinical characteristics, therapeutic strategies, treatment responses, and overall survival (OS) in patients diagnosed and treated with lymphoma-associated HLH between 2004–2012 (n = 30) and 2013–20...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Cheng-Hsien, Shih, Yu-Hsuan, Chen, Tsung-Chih, Chou, Cheng-Wei, Hsu, Chiann-Yi, Teng, Chieh-Lin Jerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584765/
https://www.ncbi.nlm.nih.gov/pubmed/34768633
http://dx.doi.org/10.3390/jcm10215114
_version_ 1784597528618991616
author Lin, Cheng-Hsien
Shih, Yu-Hsuan
Chen, Tsung-Chih
Chou, Cheng-Wei
Hsu, Chiann-Yi
Teng, Chieh-Lin Jerry
author_facet Lin, Cheng-Hsien
Shih, Yu-Hsuan
Chen, Tsung-Chih
Chou, Cheng-Wei
Hsu, Chiann-Yi
Teng, Chieh-Lin Jerry
author_sort Lin, Cheng-Hsien
collection PubMed
description To investigate the potential treatment evolution and outcome improvement, we retrospectively compared clinical characteristics, therapeutic strategies, treatment responses, and overall survival (OS) in patients diagnosed and treated with lymphoma-associated HLH between 2004–2012 (n = 30) and 2013–2021 (n = 26). Our study showed that the clinical characteristics of lymphoma-associated HLH did not substantially change over the past two decades. However, more patients diagnosed in 2013–2021 were tested for Epstein–Barr virus than those diagnosed in 2004–2012 (69.3% vs. 33.3%; p = 0.021). In addition, Eastern Cooperative Oncology Group performance status 3–4 (hazard ratio (HR): 5.38; 95% confidence intervals (CI): 2.49–11.61; p < 0.001) and jaundice (HR: 2.91; 95% CI: 1.37–6.18; p = 0.006) were poor prognostic factors for lymphoma-associated HLH. With a comparable response rate of lymphoma treatment, patients treated in 2013–2021 had a numerically greater median OS than those treated in 2004–2012 (23.6 ± 19.8 vs. 9.7 ± 4.5 months). However, the difference was not statistically significant (p = 0.334). In conclusion, early diagnosis and tailored treatments that balance efficacy and adverse events remain the key to obtaining a better outcome in lymphoma-associated HLH.
format Online
Article
Text
id pubmed-8584765
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85847652021-11-12 A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve? Lin, Cheng-Hsien Shih, Yu-Hsuan Chen, Tsung-Chih Chou, Cheng-Wei Hsu, Chiann-Yi Teng, Chieh-Lin Jerry J Clin Med Article To investigate the potential treatment evolution and outcome improvement, we retrospectively compared clinical characteristics, therapeutic strategies, treatment responses, and overall survival (OS) in patients diagnosed and treated with lymphoma-associated HLH between 2004–2012 (n = 30) and 2013–2021 (n = 26). Our study showed that the clinical characteristics of lymphoma-associated HLH did not substantially change over the past two decades. However, more patients diagnosed in 2013–2021 were tested for Epstein–Barr virus than those diagnosed in 2004–2012 (69.3% vs. 33.3%; p = 0.021). In addition, Eastern Cooperative Oncology Group performance status 3–4 (hazard ratio (HR): 5.38; 95% confidence intervals (CI): 2.49–11.61; p < 0.001) and jaundice (HR: 2.91; 95% CI: 1.37–6.18; p = 0.006) were poor prognostic factors for lymphoma-associated HLH. With a comparable response rate of lymphoma treatment, patients treated in 2013–2021 had a numerically greater median OS than those treated in 2004–2012 (23.6 ± 19.8 vs. 9.7 ± 4.5 months). However, the difference was not statistically significant (p = 0.334). In conclusion, early diagnosis and tailored treatments that balance efficacy and adverse events remain the key to obtaining a better outcome in lymphoma-associated HLH. MDPI 2021-10-30 /pmc/articles/PMC8584765/ /pubmed/34768633 http://dx.doi.org/10.3390/jcm10215114 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lin, Cheng-Hsien
Shih, Yu-Hsuan
Chen, Tsung-Chih
Chou, Cheng-Wei
Hsu, Chiann-Yi
Teng, Chieh-Lin Jerry
A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
title A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
title_full A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
title_fullStr A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
title_full_unstemmed A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
title_short A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
title_sort decade of lymphoma-associated hemophagocytic lymphohistiocytosis: does the outcome improve?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584765/
https://www.ncbi.nlm.nih.gov/pubmed/34768633
http://dx.doi.org/10.3390/jcm10215114
work_keys_str_mv AT linchenghsien adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove
AT shihyuhsuan adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove
AT chentsungchih adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove
AT chouchengwei adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove
AT hsuchiannyi adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove
AT tengchiehlinjerry adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove
AT linchenghsien decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove
AT shihyuhsuan decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove
AT chentsungchih decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove
AT chouchengwei decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove
AT hsuchiannyi decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove
AT tengchiehlinjerry decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove